drugset
drugset / Trial / NCT01365000

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

NCT01365000 ↗

Phase 1 Completed 21 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.

Timeline

Start
2011-06
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxegol Small molecule 25 mg Oral

Indications

No indication recorded.